THC vs CBD at the endocannabinoid system

TL;DR

• THC: partial CB1/CB2 agonist → psychoactive.
• CBD: negative allosteric CB1 modulator, no high.
• CBD also acts at 5-HT1A, TRPV1, GPR55, PPARγ.
• CBD can dampen THC's effect (Boggs 2018).

Why isn't CBD a 'CB1 antagonist'?

CBD doesn't bind the orthosteric site like a classic antagonist — it binds an allosteric pocket and changes receptor conformation, so agonists like THC dock less well. This explains why CBD can blunt THC's anxiety and tachycardia without cancelling analgesia (Laprairie 2015).

Pharmacodynamic synergy and the entourage effect

In practice, it is evident that the effects of cannabis go beyond looking at THC and CBD in isolation. The interplay of phytocannabinoids and plant terpenes decisively shapes the overall pharmacological profile of a strain. This phenomenon suggests that the plant's various constituents can influence each other's absorption and receptor binding. While isolated THC often produces highly intense psychoactive peaks, the simultaneous presence of CBD and specific aromatic compounds ensures a gentler and more tolerable effect on the human body.

This synergy is of great importance for targeted modulation of the endocannabinoid system, as multiple biological signaling pathways are addressed simultaneously. Terpene can, for example, alter the permeability of cell membranes or bind directly to receptors, thereby influencing the affinity of cannabinoids. As a result, the therapeutic spectrum shifts depending on the chemical composition of the plant. This explains why different cannabis strains, despite having identical active ingredient concentrations, are often perceived very differently by consumers in terms of their physiological and psychological effects.

• Interaction between phytocannabinoids and plant terpenes
• Modulation of biological barriers for altered bioavailability
• Potential mitigation of adverse effects through synergistic mechanisms
• High relevance of full-spectrum extracts compared to pure isolates

Therapeutic management and medical practice

Understanding receptor interaction forms the basis for precise dosing in the medical field. Since August 2022, medical cannabis has been directly prescribable by physicians in Switzerland without an exceptional permit from the Federal Office of Public Health (FOPH). Medical professionals systematically leverage the interplay of active ingredients by prescribing preparations with defined THC-to-CBD ratios. This allows the analgesic properties of THC to be utilized, while the dampening properties of CBD help minimize unwanted psychotropic side effects such as anxiety or tachycardia.

However, clinical experience shows that responses to these combinations vary widely from individual to individual. Since each person's endocannabinoid system is unique and receptor density fluctuates, the dosage must always be adjusted gradually. Swiss physicians base their therapy on the current body of evidence, which indicates relief for certain chronic conditions or spasticity. In many cases, the combination of both primary active ingredients makes it possible to significantly reduce the required dose of psychoactive THC compared to monotherapy.

• Direct medical prescribability in Switzerland since August 2022
• Combination of THC and CBD to reduce side effects in daily clinical practice
• Individual dose finding based on the unique receptor distribution in the body
• Use of standardized extracts for a controllable and safe therapy

Regulatory limits and road safety in Switzerland

For consumers in Switzerland, the distinction between THC- and CBD-rich products is of central legal importance. Hemp products with a total THC content of less than one percent are not considered illegal substances under the Narcotics Act and are freely available for sale. As soon as this limit is exceeded, consumption and possession in public spaces are generally prohibited, unless there is a medical prescription or one participates in one of the government-approved, scientifically monitored pilot trials in Swiss cities.

In Swiss road traffic, a strict zero-tolerance policy applies regarding THC. The legal detection limit in the blood is a mere 1.5 micrograms per liter, which can be exceeded even after consuming legal CBD hemp with minimal traces of THC. Anyone caught behind the wheel with this level is legally deemed unfit to drive, which entails severe administrative and criminal consequences. Consumers must therefore be aware of the long half-life and accumulation of THC in adipose tissue.

• Legal limit of less than one percent total THC for legal products
• Strict zero-tolerance policy in road traffic with a limit of 1.5 micrograms per liter of blood
• Opportunity to participate in scientifically monitored pilot trials in selected cities
• Risk of cumulative THC levels in the body, even with regular CBD consumption

FAQ